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 2 
Abstract  26 
Recognition of Influenza A virus (IAV) by the innate immune system triggers pathways that 27 
restrict viral replication, activates innate immune cells, and regulates adaptive immunity. 28 
However, excessive innate immune activation can exaggerate disease. The pathways 29 
promoting excessive activation are incompletely understood, with limited experimental 30 
models to investigate mechanisms driving influenza-induced inflammation in humans. 31 
Interferon regulatory factor (IRF5) is a transcription factor that plays important roles in 32 
induction of cytokines after viral sensing. In an in vivo model of IAV infection, IRF5 33 
deficiency reduced IAV-driven immune pathology and associated inflammatory cytokine 34 
production, specifically reducing cytokine-producing myeloid cell populations in Irf5
-/-
 mice, 35 
but not impacting type 1 IFN production or virus replication. Using cytometry by time-of-36 
flight (CyTOF), we identified that human lung IRF5 expression was highest in cells of the 37 
myeloid lineage. To investigate the role of IRF5 in mediating human inflammatory responses 38 
by myeloid cells to IAV, we employed human induced pluripotent stem cells (hIPSCs) with 39 
biallelic mutations in IRF5, demonstrating for the first time iPS-derived dendritic cells (iPS-40 
DCs) with biallelic mutations can be used to investigate regulation of human virus-induced 41 
immune responses. Using this technology, we reveal that IRF5 deficiency in human DCs, or 42 
macrophages, corresponded with reduced virus-induced inflammatory cytokine production, 43 
with IRF5 acting downstream of TLR7 and, possibly, RIG-I after viral sensing. Thus, IRF5 44 
acts as a regulator of myeloid cell inflammatory cytokine production during IAV infection in 45 
mice and humans, and drives immune-mediated viral pathogenesis independently of type 1 46 
IFN and virus replication. 47 
 48 
 49 
 50 
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 3 
Importance 51 
The inflammatory response to Influenza A virus (IAV) participates in infection control but 52 
contributes to disease severity. After viral detection intracellular pathways are 53 
activated, initiating cytokine production, but these pathways are incompletely 54 
understood. We show that interferon regulatory factor 5 (IRF5) mediates IAV-induced 55 
inflammation and, in mice, drives pathology. This was independent of antiviral type 1 IFN 56 
and virus replication, implying that IRF5 could be specifically targeted to treat influenza-57 
induced inflammation. We show for the first time that human iPSC technology can be 58 
exploited in genetic studies of virus-induced immune responses. Using this technology, we 59 
deleted IRF5 in human myeloid cells. These IRF5-deficient cells exhibited impaired 60 
influenza-induced cytokine production and revealed that IRF5 acts downstream of Toll-like 61 
receptor 7 and possibly retinoic acid-inducible gene-I. Our data demonstrate the importance 62 
of IRF5 in influenza-induced inflammation, suggesting genetic variation in the IRF5 gene 63 
may influence host susceptibility to viral diseases. 64 
 65 
Introduction 66 
During infection with Influenza A virus (IAV), the host immune system must calibrate 67 
immune responses to control viral infection, whilst minimizing damage to host tissues. 68 
Disease manifestations are often associated with host inflammatory response to the virus (1, 69 
2), and clinical outcome varies widely between individuals (3). The inflammatory response is 70 
initiated when pattern recognition receptors (PRRs) on innate immune cells recognize IAV 71 
pathogen-associated molecular patterns (PAMPs), which trigger signaling cascades resulting 72 
in the expression of specific inflammatory cytokines and chemokines (4, 5). Cytokines play 73 
various roles, such as directly inhibiting viral replication and activating the cytolytic 74 
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 4 
functions of T-cells, whereas chemokines recruit innate immune cells such as macrophages, 75 
neutrophils, NK cells and inflammatory monocytes to the lungs and airways (6).  76 
    77 
Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, 78 
whose members have a shared N-terminal DNA binding domain and bind consensus 79 
interferon stimulated response element (ISRE) motifs. As ISREs are enriched in the 80 
regulatory regions of immune genes, IRFs play key roles as master regulators in the innate 81 
immune response (7), and may provide a mechanism for conferring signal specificity to 82 
target gene sets downstream of TLR signaling (8). Whilst IRF3 and IRF7 are necessary for 83 
induction of type I interferon (9, 10), IRF5 has been shown to be key in regulating 84 
inflammatory cytokine responses, generally acting downstream of TLR-MyD88 pathways 85 
(11, 12). Genetic polymorphisms in the IRF5 gene in humans have been linked to various 86 
autoimmune conditions including systemic lupus erythematosus, rheumatoid arthritis, 87 
Sjogren’s syndrome, multiple sclerosis and inflammatory bowel disease (13). IRF5 has also 88 
been shown to be important in regulating immune responses to various pathogens in murine 89 
and human cell models (14–17). Additionally, Irf5-/- mice are resistant to systemic shock 90 
induced by CpG ligands and Lipopolysaccharide (LPS) (12). The extent to which IRF5 91 
contributes to inflammation-induced pathologies, however, is unclear. 92 
 93 
IRF5 is expressed predominantly by myeloid cells such as dendritic cells (DCs) and 94 
macrophages, in addition to B cells (13, 18). Myeloid cells can have protective and immune-95 
pathogenic roles during IAV infection, producing inflammatory cytokines and initiating 96 
adaptive immune responses (19). Furthermore, inflammatory monocytes and monocyte-97 
derived DCs have been identified to drive inflammation and lung pathology during IAV 98 
infection (19, 20). 99 
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 5 
Studying inflammatory cytokine responses in human myeloid cells is challenging. Human 100 
DCs are difficult to culture in vitro and, although DCs can be induced from blood-derived 101 
monocytes, these cells display morphological and functional differences to human primary 102 
DCs, for example differing in their capacity for T cell stimulation in comparison to CD11c
+
 103 
blood-derived DCs (21). Primary myeloid cells are also difficult to genetically manipulate, 104 
meaning that studies addressing the effect of host genetics on myeloid cell responses can be 105 
challenging. Human induced pluripotent stem cells (hIPSCs) offer a useful system for 106 
studying host-pathogen variation, because these cells are amenable to genetic manipulation, 107 
can be differentiated toward multiple cellular lineages and are self-renewing, allowing for 108 
production of sufficient quantities of cells of the same genetic background. hIPSC-derived 109 
macrophages (iPSDMs) have already been used to successfully model the interactions of 110 
pathogens with host cells (16, 22). However, to date, hIPSC technology has not been used to 111 
perform genetic investigations of virus-induced immune responses. To study the impact of 112 
IRF5 on human myeloid IAV-induced immune responses, we utilized hIPSCs generated from 113 
a healthy donor, or with mutations in IRF5 generated by CRISPR/Cas9 engineering, 114 
differentiated into dendritic cells and macrophages as a human model system to assess the 115 
role of IRF5 in the regulation of immune responses to IAV. Using these tools in combination 116 
with studies of human lung cells, in addition to Irf5
-/-
 mice, we show that IRF5 drives IAV-117 
induced inflammatory cytokine responses in mice and humans without impacting virus 118 
replication and type 1 IFN secretion, and this process mediates viral pathogenesis in vivo.  119 
 120 
 121 
 122 
 123 
 124 
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 6 
Materials and Methods 125 
 126 
Mice and viral infections 127 
Irf5
−/−
 mice were bred in-house on a C57BL/6 background and their generation has been 128 
described previously (12). C57BL/6 WT mice were purchased from Charles River or Envigo. 129 
Age- and sex-matched mice between 7 and 12 weeks of age were used in the experiments. 130 
Mice were infected intranasally with 3 x 10
3 
PFU A/X-31 influenza in 50μl of sterile PBS. 131 
Mice weight was recorded daily and further monitored for signs of illness.  132 
 133 
Plaque assays 134 
Influenza from lungs of WT and Irf5
-/-
 mice was quantified on Madin–Darby canine kidney 135 
(MDCK) cell monolayers after a 5-hour incubation at 37C. Cell layers were then overlaid 136 
with methylcellulose (Sigma-Aldrich) and incubated at 37 °C for a further 48 hours. Media 137 
was then removed, and cell layers were washed, fixed and blocked and further incubated with 138 
anti-Influenza A nucleoprotein (Clone AA5H, Serotec) and then with anti-mouse IgG-HRP 139 
(BioRad). Plaques were developed using AEC peroxidase substrate solution and subsequently 140 
counted via light microscopy. 141 
   142 
Leukocyte isolation, intracellular cytokine staining, and flow cytometry 143 
BAL and lungs were collected from Irf5
-/-
 and WT mice at days 2, 4 and 7 p.i. Lung digests 144 
were performed by incubation with collagenase solution (RPMI supplemented with 5% FBS, 145 
1mg/ml collagenase D (Roche), 5 mM CaCl2, 50 mg/mL DNAse I (Sigma-Aldrich)), and 146 
single cell suspensions were generated by passing through 100 M filters. Cells were stained 147 
with Zombie Aqua fixable dye, incubated with anti-mouse CD16/CD32 (both BioLegend), 148 
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 7 
and stained for surface markers with a combination of the following antibodies (all 149 
BioLegend, BD Biosciences or Miltenyi Biotech). For murine myeloid panels cells were 150 
stained for surface markers: anti-mouse CD11b-FITC (M1/70, BioLegend), Ly6C-151 
PerCP/Cy5.5 (HK1.4, BioLegend), Siglec F-PeVio770 (ES22-10D8, Miltenyi Biotec), 152 
CD64-Pe/Dazzle (X54-5/7.1, BioLegend), CD45R/B220-APC/Cy7 (RA3-6B2, BioLegend), 153 
MHC II-BV711 (M5/114.15.2, BioLegend), CD11c-BV605 (N418, BioLegend) and Siglec 154 
H-Pacific Blue (551, BioLegend). Following surface staining, some cells were fixed and 155 
permeabilized with Fixation/Permeabilization solution (BD Biosciences) and stained with 156 
anti–IL-6-PE (MP5-20F3; BioLegend) and TNF--APC (MP6-XT22, BioLegend). All data 157 
was acquired using an Attune NxT flow cytometer (Thermo Fisher Scientific). Electronic 158 
compensation was performed with Ab capture beads stained separately with individual mAbs 159 
used in the experimental panel. Data were analyzed using FlowJo software (TreeStar Inc). 160 
Total numbers of different cell populations were calculated by multiplying the total number 161 
of viable leukocytes (assessed by trypan blue exclusion) by the percentage of positive cells, 162 
as detected by flow cytometry. 163 
 164 
Mass Cytometry staining for IRF5 expression 165 
Para-tumor lung tissue samples from metastatic cancer or fibrosis patients were extracted and 166 
deemed to show no visible signs of inflammation by a pathologist. PBMC from one donor 167 
were run with each lung sample to control for inter-run variability.  100 mL of heparinized 168 
blood was drawn from a healthy control donor, PBMCs were isolated and aliquots were 169 
frozen until use. Directly conjugated antibodies (CD45-89Y, clone HI30; EpCAM-141Pr, 170 
clone 9C4; CD31-151Eu, clone EPR3094; CD68-159Tb, clone KP1; Siglec 8-164Dy, clone 171 
7C9) were all purchased from Fluidigm. Conjugations for other antibodies (CD11b-142Nd, 172 
clone ICRF44; CD4-145Nd, clone RPA-T4; CD20-147Sm, clone 2H7; CD115-152Sm, clone 173 
 o
n
 M
arch 2, 2020 at CAM
BRIDG
E UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
 8 
12-3A3-1810; CD123-155Gd, clone 6H6; CD14-160Gd, clone M5P2; CD56-166Er, clone 174 
NCM/HCD56; CD8-168Er, clone SK1; HLA-DR-169Tm, clone L243; CD3-170Er, clone 175 
UCHT1; CD1c-171Yb, clone L161; CD141-173Yb, clone M80) were performed with the 176 
Maxpar X8 Multi-Metal Labeling Kit (Fluidigm) according to the manufacturer’s 177 
instructions. 178 
 179 
Cells re-suspended at 1×10
7
 cells/mL were stained with 5 mmol/L Cisplatin (Fluidigm; 180 
live/dead) and surface antibody cocktail before permeabilization with Maxpar nuclear antigen 181 
staining buffer and staining with anti-IRF5 (Conjugate, 175Lu; clone, EPR17067). An un-182 
permeabilized control was treated with cell staining buffer and stained with intracellular 183 
antibodies. Cells were stained with 125 nM Ir-Intercalator (Fluidigm) according to Fluidigm 184 
protocols and fixed with 1.6% formaldehyde. Cells were counted on a BD Accuri C6, and 185 
resuspended at 2×10
6
 cells/mL in 0.1×EQ Four Element Calibration Beads (Fluidigm). Cells 186 
were acquired using a CyTOF Helios cytometer (Fluidigm). Data was processed and 187 
normalized using the CyTOF software v6.7 (Fluidigm).  Data was analyzed using FlowJo 188 
(Treestar Inc).  189 
 190 
Mass cytometry Analysis 191 
CyTOF data were analyzed using FlowJo 10.5.2 (TreeStar Inc).  After gating on live, intact, 192 
singlet cells, CD45 v EpCAM expression was used to identify epithelial cells (CD45
-
 193 
EpCAM
+
) or immune cells (CD45
+
EpCAM
-
). CD45
+
EpCAM
-
 cells were down-sampled to 194 
maximum 200,000 per sample, with stained and control samples were concatenated into one 195 
file. The concatenated file was run through a UMAP analysis of the surface markers CD11b, 196 
CD4, CD20, CD123, CD68, CD14, Siglec 8, CD56, CD8, HLA-DR, CD3, CD1c, CD141, 197 
CD16. Post-UMAP analysis, distinct cell subsets were identified by mapping expression of 198 
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 9 
specific subset markers back onto the UMAP to define populations of immune cells. Subsets 199 
were defined as follows: CD4
+
 T cells, CD3
+
CD4
+
CD20
-
; CD8
+
 T cells, CD3
+
CD20
-
CD8
+
; B 200 
cells, CD3
-
CD20
+
; NK cells, CD3
-
CD20
-
CD56
+
; CD14
+
 Monocytes, CD16
-
201 
CD11b
+
CD14
+
HLA-DR
+
; CD16
+
 Monocytes, CD14
-
CD11b
+
CD16
+
HLA-DR
+
; 202 
Macrophages, CD11b
+
CD68
+
HLA-DR
+
; pDCs, CD123
+
CD11b
+
HLA-DR
+
; CD141
+
 cDCs, 203 
CD11b
+
HLA-DR
+
CD1c
-
CD141
+
; CD1c
+
 cDCs, CD11b
+
HLA-DR
+
CD1c
+
CD141
-
; 204 
Eosinophils, Siglec8
+
CD123-; Basophils, Siglec8
+
CD123
+
; Epithelial cells, CD45
-
 EpCAM
+
. 205 
Individual samples were identified by gating on event length v sample ID, and the median 206 
value was determined for IRF5 for each individual sample.  207 
 208 
Generation of blood-derived human dendritic cells 209 
PBMCs from three independent donors were isolated from leukapheresis products using 210 
Lymphoprep density gradient centrifugation and SepMate PBMC isolation tubes (StemCell 211 
Technologies), under the Weatherall Institute of Molecular Medicine, University of Oxford 212 
Human Tissue Authority License (12433). Human CD14 microbeads were used in 213 
combination with LS columns (both Miltenyi Biotec) to positively select CD14
+
 blood 214 
monocytes. CD14
+ 
cells were seeded at a density 3-5×10
6
 isolated monocytes in 3 mL of 215 
RPMI media supplemented with 10% heat inactivated Fetal Bovine Serum (FBS; Sigma-216 
Aldrich), 250 IU/mL IL-4 and 800 IU/mL GM-CSF into a 6-well plate and incubated at 37C 217 
for 2 days. After 2 days 1.5ml of medium was removed from each well, and 1.5 mL of fresh 218 
medium supplemented with 500 IU/mL IL-4 and 1600 IU/mL GM-CSF was added. After a 219 
further 3-day incubation, cells were harvested at the immature phenotype and assayed, or 220 
further matured with LPS at 10 g/mL for 24 hours.  221 
 222 
 223 
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 10 
hIPSCs 224 
The healthy control hIPSC line Kolf2 was acquired through the Human Induced Pluripotent 225 
Stem Cells Initiative Consortium (HipSci; www.hipsci.org), through which it was also 226 
characterized (23). Generation of IRF5
-/-
 iPSCs has been previously described (16). Briefly, 227 
Kolf2 iPSCs were dissociated to single cells and nucleofected (Amaxa2b nucleofector, 228 
LONZA) with Cas9 coding plasmid (hCas9, Addgene 41815), sgRNA plasmid (left 229 
CRISPR_IRF5 CCAAGTGGAAGGCCAACCTGCGC; right CRISPR_IRF5 230 
GACTTCCGCCTCATCTACGACGG) and donor plasmid, containing 5’ and 3’ homology 231 
arms for IRF5 targeting and pL1-EF1αPuro-L2 cassette. Post nucleofection, cells were 232 
selected for up to 11 days with 0.25 μg/mL puromycin, after which individual colonies were 233 
picked onto 96-well plates, grown to confluence and then replica plated. To genotype 234 
individual clones from a 96-well replica plates, cells were lysed and used for PCR 235 
amplification with LongAmp Taq DNA Polymerase (NEB). Insertion of the cassette into the 236 
correct locus was confirmed by visualizing on 1% E-gel (Life Tech.) PCR products were 237 
generated by gene specific and cassette specific primers, with single integration of cassette 238 
confirmed by a qPCR copy number assay. Positive clones were then screened for damage to 239 
the non-targeted allele via PCR and Sanger sequencing. To generate our complemented IRF5 240 
iPSC line (IRF5
Comp
) and restore expression of functional IRF5 in the IRF5
-/-
 iPSCs, we 241 
generated the AAVS1 EF1a-IRF5-PGK-puro targeting vector by Gibson assembly. The 242 
Gibson assembly product was transformed into OneShot TOP10 chemically competent E. 243 
coli (Thermo Fisher Scientific) and positive colonies were picked. Isolated plasmids from the 244 
positive colonies were taken to confirm the presence and sequence of EF1α-IRF5 in the 245 
targeting vector by restriction digests, PCR and sequencing. Subsequently, the targeting 246 
vector was transformed into competent E. coli to isolate endotoxin-free plasmids to transform 247 
into the IRF5
-/-
 iPSCs. We transfected the mutant human hIPSCs with TALEN-L 248 
 o
n
 M
arch 2, 2020 at CAM
BRIDG
E UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
 11 
(CCCCTCCACCCCACAGT), TALEN-R (AGGATTGGTGACAGAAA) and targeting 249 
vector via nucleofection (Amaxa Biosystems). The resultant targeted cells were selected on 250 
puromycin for 7 days and the surviving colonies were picked and expanded. The positive 251 
clones were confirmed by RT-qPCR for IRF5 expression and flow cytometry for protein 252 
expression. Prior to differentiation, iPSCs were grown feeder-free using the Essential 8 Flex 253 
Medium kit (Thermo Fisher Scientific) on Vitronectin (VTN-N, Thermo Fisher Scientific) 254 
coated plates as per manufacturer’s instructions to 70-80% confluency. iPSCs were harvested 255 
for differentiation using Versene solution (Thermo Fisher Scientific).  256 
 257 
Differentiation of iPSCs to dendritic cells and macrophages 258 
To differentiate iPSCs to dendritic cells slight modifications were made to a previously 259 
published protocol (24). Briefly, upon reaching confluency iPSCs were harvested and plated 260 
into Essential 8 Flex medium supplemented with 50 ng/mL BMP-4 (Bio-Techne), 20 ng/mL 261 
SCF (Bio-Techne), 50 ng/mL VEGF (Peprotech EC Ltd.), and 50ng/mL GM-CSF (Peprotech 262 
EC Ltd.) in ultra-low attachment plates (Corning). Media was changed to X-VIVO-15 263 
(Lonza), with sequential removal of BMP-4 by day 5, VEGF by approximately day 14 and 264 
SCF by approximately day 19. In addition, IL-4 (Peprotech EC Ltd.) was added sequentially 265 
in increasing concentrations, starting from approximately day 12 at 25 ng/mL and increasing 266 
to 100 ng/mL by approximately day 20. By day 20, floating immature DCs were harvested 267 
from ULA plates, filtered through 70M filters (Corning), counted and seeded at 1 x 106 per 268 
well of 6 well CellBind plates (Corning) in X-VIVO-15 media supplemented with 100 ng/mL 269 
IL-4 and 50 ng/mL GM-CSF. iPS-DCs were used for assays at the immature phase between 270 
4-5 days post seeding in CellBind plates. In addition, iPS-DCs could be matured for a further 271 
48 hours 5 days post plating, by addition of 50 ng/ml of GM-CSF, 100 ng/ml IL-4, 20 ng/ml 272 
IFN (Bio-Techne), 50 ng/ml TNF (Bio-Techne), 10 ng/ml IL-1 (Bio-Techne) and 1 g/ml 273 
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 12 
PGE2 (Sigma-Aldrich), to induce further expression of CD141
+
 DC lineage markers. For 274 
assays, floating iPS-DCs were harvested from differentiation plates, washed with PBS, 275 
counted and seeded in X-VIVO-15 media without cytokines at an assay dependent 276 
concentration. To differentiate iPSCs to macrophages, the approach of Hale et al (22) and van 277 
Wilgenburg et al (25) was modified to allow for feeder-free differentiation. Briefly, upon 278 
reaching confluency, human iPSCs were collected and transferred into Essential 8 Flex 279 
medium supplemented with 50 ng/mL BMP-4 (Bio-Techne), 20 ng/mL SCF (Bio-Techne) 280 
and 50 ng/mL VEGF (Peprotech EC Ltd.) in ultra-low attachment plates (Corning) for 4 days 281 
to generate Embryoid Bodies (EBs). On day 5, EBs were used for generation of myeloid 282 
precursor cells by plating into 6-well tissue culture treated plates (Corning) coated for two 283 
hours at room temperature with 0.1% gelatin, in X-VIVO-15 media supplemented with 284 
25 ng/mL IL-3 (Bio-Techne) and 50 ng/mL M-CSF (Bio-Techne). After several weeks, 285 
floating myeloid precursors were harvested and terminally differentiated into matured 286 
macrophages (iPSDMs) in the presence of higher concentrations of M-CSF (100 ng/mL) for 7 287 
days. For experiments, macrophages were detached using Lidocaine solution (4 mg/mL 288 
lidocaine-HCl with 10 mM EDTA in PBS), and seeded at 2 × 105 cells per well (24-well 289 
plate) or 1 × 10
6
 cells per well (six-well plate). 290 
 291 
Preparation of RNA and RT-qPCR 292 
iPS-DCs were harvested from plates and RNA was prepared using the RNeasy minikit 293 
(Qiagen). RNA was reverse transcribed with the QuantiTect reverse transcription (RT) kit 294 
(Qiagen) according to the manufacturer’s protocol. All RT-qPCR experiments were 295 
performed with TaqMan gene expression assays and TaqMan gene expression master mix 296 
(Applied Biosystems) on the Applied Biosystems StepOne real-time PCR system. RT-qPCR 297 
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 13 
data were analyzed via the comparative CT method with glyceraldehyde 3-phosphate 298 
dehydrogenase (GAPDH) as an endogenous control. 299 
 300 
Flow cytometric analysis of iPS-DCs 301 
For analysis of surface markers on iPS-DCs, cells were stained with Zombie Aqua fixable 302 
dye (BioLegend), Fc receptors were blocked using Human TruStain FcX (BioLegend) and 303 
cells were then subsequently stained for surface markers with a combination of the following 304 
antibodies: anti-human HLA-DR-AlexaFluor488 (AF488) (L243, BioLegend) or CD14-FITC 305 
(M5E2, BioLegend), CD83-PerCP/Cy5.5 (HB15e, BioLegend) or CD1c-PerCP/Cy5.5 (L161, 306 
BioLegend), CD141-PE/Cy7 (M80, BioLegend) or DC-SIGN-PE/Cy7 (9E9A8, BioLegend), 307 
or XCR1-PE (FAB8571, Bio-Techne), CD11c-APC/Cy7 (Bu15, BioLegend), CLEC9A-APC 308 
(8F9, BioLegend), CD86-BV711 (IT2.2, BioLegend), CD303-BV785 (201A, BioLegend) or 309 
HLA-DR-BV785 (L243, BioLegend), or HLA-A,B,C-Pacific Blue (W6/32, BioLegend). For 310 
detection of IRF5 or IAV nucleoprotein, cells were stained with Zombie Aqua fixable dye, 311 
fixed with 4% Paraformaldehyde and permeabilized with 0.5% Triton X, followed by 312 
incubation with Human TruStain FcX and staining with IRF5-AF647 (EPR6094, Abcam) or 313 
Anti-Influenza A Virus Nucleoprotein antibody (431, Abcam) in 0.1% Triton X solution. All 314 
data was acquired using a BD LSRFortessa flow cytometer (BD Biosciences). Electronic 315 
compensation was performed with Ab capture beads stained separately with individual mAbs 316 
used in the experimental panel. Data were analyzed using FlowJo software (TreeStar Inc).  317 
 318 
Infection of iPS-DCs and iPSDMs with IAV 319 
iPS-DCs, iPSDMs or human moDCs were infected with A/X-31 influenza at an MOI of 1 by 320 
addition of virus to culture supernatant and centrifugation at 630 g for 20 minutes at room 321 
temperature, after which media was replaced with fresh culture medium.  322 
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 14 
Immunostaining for confocal microscopy 323 
iPS-DCs were harvested from plates and spun onto slides coated with 0.01% Poly-l-Lysine 324 
using a Cytospin cytocentrifuge. Samples were blocked and permeabilized in 2% Triton X-325 
100 (Sigma-Aldrich) in 5% FBS diluted in PBS. Primary antibodies were applied at room 326 
temperature in 0.25% Triton X-100 in 5% FBS diluted in PBS for 1 hour and then rinsed 3 327 
times with PBS. Secondary antibodies were applied in the same manner. Nuclei were 328 
counterstained with 10 nM DAPI dilactate diluted in PBS for 30 min, samples were rinsed 6 329 
times with PBS, and then mounted in Prolong-Gold with added DAPI (Invitrogen) and 330 
analyzed using a Leica SP8 DLS (Digital light sheet) microscope.  331 
 332 
TLR/RIG-I stimulations  333 
iPS-DCs were plated at 1 x 10
4
 cells per well in 200ul of X-VIVO-15 media without 334 
cytokines. TLR ligands were added directly to the media, and supernatants were harvested 335 
after 24-hour incubation at 37C. For assays TLR ligands were used at the following 336 
concentrations: Pam3CSK4 (300 ng/mL; InvivoGen), Poly I:C (50 g/mL; InvivoGen), 337 
Lipopolysaccharide (500 ng/mL; Sigma-Aldrich), Imiquimod (50 g/mL; InvivoGen); ODN 338 
2216 (3 g/mL; Miltenyi Biotech). For RIG-I stimulation 1 g of 3p-hpRNA was complexed 339 
with LyoVec (InvivoGen) for 15 minutes at room temperature and then added to iPS-DCs at 340 
10 ng/mL.   341 
   342 
Cytokine and chemokine analysis 343 
Human IL-6 and TNF- protein was measured by ELISA (BioLegend). ELISAs for human 344 
IFN- and IFN-β were performed on supernatants harvested from mock infected and IAV 345 
infected iPS-DCs using the Verikine Human Interferon Alpha/Interferon Beta ELISA kit 346 
(PBL Assay Science). Murine BAL cytokines were detected using the LEGENDPlex mouse 347 
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inflammation panel (13-plex; BioLegend) as per the manufacturer’s instructions at 2, 4 and 6 348 
days p.i. and analyzed using the LEGENDPlex analysis software. ELISAs for mouse IFN- 349 
and IFN-β were performed on BAL from naïve mice and mice 2 days p.i using VeriKine 350 
Mouse Interferon Alpha/Interferon Beta ELISA Kits (PBL Assay Science).  351 
 352 
Blocking assays 353 
For blocking assays cells were either pre-incubated for 1 hour with inhibitor (IMD 0354; 354 
IKK inhibitor, (Santa Cruz Biotechnology) 5 g/mL)) or inhibitor was added directly with 355 
viral inoculum (TLR7 inhibitor, ODN 20958, Miltenyi Biotech, 5 M). For type I IFN 356 
blocking, cells were pre-incubated with 5 g/mL anti-IFNAR1 antibody (Sigma-Aldrich) for 357 
1 hour prior to infection with A/X-31 influenza without removal of antibody. 358 
 359 
Statistical analysis  360 
Statistical significance was performed with GraphPad Prism software. Mann Whitney-U or 361 
Student's t-tests were used for two-group comparisons. For comparison of IRF5 expression 362 
between lung cell subsets identified via CyTOF a repeated measurement one-way ANOVA 363 
was used. A p value of ≤ 0.05 was considered to be significant. For all tests performed, p 364 
values are reported as n.s. > 0.05; *  0.05; ** 0.01; ***  0.001; ****  0.0001 365 
 366 
Ethics statement 367 
All animal studies were performed at Cardiff University (Heath Park research support 368 
facility) under UK Home Office Project License number (P7867DADD), as approved by the 369 
UK Home Office, London, United Kingdom. Written consent was obtained for the use of cell 370 
lines for the HIPSCI project from healthy volunteers. A favorable ethical opinion was granted 371 
by the National Research Ethics Service (NRES) Research Ethics Committee Yorkshire and 372 
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The Humber – Leeds West, reference number 15/YH/0391. Lung tissue samples were 373 
obtained from lung cancer and fibrosis patients from Oxford Radcliffe Biobank with written 374 
consent: a favorable ethical opinion was granted by the South Central-Oxford C Research 375 
Ethics Committee for collection and frozen storage of both tumor and para-tumor lung 376 
samples (Reference number: 09/H0606/5+5).  377 
 378 
Results 379 
 380 
IRF5 mediates inflammatory cytokine and myeloid cell responses to Influenza A virus 381 
infection in mice  382 
The mouse is the primary experimental model for studying immunological response to IAV, 383 
where it has been demonstrated that excessive inflammatory cytokine and cellular immune 384 
responses promote lung pathology (2, 26, 27). We first used this model to assess whether 385 
IRF5 impacts influenza-induced immune responses during IAV infection in vivo, using the 386 
low pathogenicity murine-adapted H3N2 Influenza A virus (A/X-31). Prior studies have 387 
indicated that viral infections of Irf5
-/-
 mice lead to reduced cytokine production in 388 
comparison to wild type (WT) controls (14, 17, 28). In accordance, we observed a significant 389 
reduction in early cytokine release in Irf5
-/-
 mice, with IL-23, IFN-, TNF-, MCP-1, IL-6, 390 
IL-17A, IL-1, IL-12p70, GM-CSF, IL-1 and IL-27 all significantly reduced in the 391 
Bronchoalveolar Lavage (BAL) of Irf5
-/-
 mice in comparison to WT controls 2 days post-392 
infection (p.i) (Fig. 1A), with some cytokines remaining significantly reduced in Irf5
-/-
 mice 4 393 
days p.i (Fig. 1A). In contrast to other viral infections (17), IFN- or IFN- production in 394 
response to influenza infection were unaltered (Fig. 1B) at a time-point (day 2 p.i) previously 395 
demonstrated to represent the time of significant A/X-31 influenza-induced type 1 IFN 396 
secretion in this model (29). These data therefore imply that IRF5 selectively modulates 397 
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expression of certain influenza-induced inflammatory cytokines independently of type I IFNs 398 
in mice.  399 
 400 
Early reduction in inflammatory cytokine production in Irf5
-/-
 mice was accompanied by a 401 
moderate amelioration of IAV-induced weight loss (Fig. 2A). Interestingly, a recent study 402 
reported that reduced IAV-induced cytokine production in Irf5
-/-
 mice was associated with 403 
reduced virus replication (28). However, at a time-point where we observed substantially 404 
reduced cytokine production (day 2 p.i), we observed no alteration in IAV load in Irf5
-/-
 mice 405 
(Fig. 2B), nor did we observe altered virus load in Irf5
-/-
 mice at a later timepoint of 4 days p.i 406 
(Fig. 2B). Thus, our data demonstrates for the first time that IRF5 promotes IAV-induced 407 
weight loss independently of an impact on influenza replication.   408 
 409 
Given the established role for myeloid cells in pulmonary inflammation during IAV infection 410 
(30, 31), we used polychromatic flow cytometry panels to assess whether Irf5 influenced 411 
myeloid cell accumulation during infection. Reductions in monocyte-derived DCs, interstitial 412 
macrophages, inflammatory monocytes and conventional DCs in the lungs of Irf5
-/-
 mice 413 
were observed at 2 days p.i (Fig. 2C). Importantly, lower cytokine responses in Irf5
-/-
 mice 414 
were accompanied by significant reductions in IL-6
+
 cDCs and TNF-+ cDCs, interstitial 415 
macrophages, cDCs and pDCs in the airways (Fig. 2D). Thus, these data suggested that Irf5 416 
plays a key role in shaping the early innate inflammatory response during influenza infection 417 
and point to a central role for myeloid cells in promoting IRF5-driven viral disease. 418 
 419 
Myeloid cells in human lung express high levels of IRF5 420 
Although the mouse is a useful model for probing immune responses to IAV, numerous 421 
differences exist between the mouse and human immune system. It was therefore important 422 
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to investigate the role of human IRF5 in IAV-induced immune responses. We first measured 423 
IRF5 expression in multiple cell subsets in human lung samples using CyTOF (Fig. 3A). 424 
Using lung samples from four independent donors, we identified significantly different IRF5 425 
expression dependent on cell subset (p = 0.0252, R-Square = 0.9098) (Fig. 3B), with cells of 426 
the myeloid lineage, particularly eosinophils, basophils and monocytes, displaying highest 427 
expression of IRF5 in human lung. Expression was higher in CD1c
+
 DCs and CD141
+
 DCs 428 
than in lung resident macrophages, where expression was relatively low.  Furthermore, when 429 
IRF5 expression data was combined for all myeloid cell subsets and all lymphoid cell subsets 430 
(Fig. 3C), expression of IRF5 was significantly higher in myeloid cells in comparison to 431 
lymphoid cells (median expression myeloid = 6.01, median expression lymphoid = 1.79; p = 432 
0.0001), suggesting that IRF5 expression is highest in the myeloid compartment.     433 
 434 
iPSCs with a biallelic mutation in IRF5 can be differentiated into conventional dendritic 435 
cells  436 
Given that, in the human lung, IRF5 expression was highest in cells of the myeloid lineage 437 
and that in mice Irf5 promoted pro-inflammatory cytokine production by myeloid cells in 438 
response to IAV infection, we next sought to establish a human myeloid cell model to 439 
scrutinize the role of IRF5 in myeloid cell cytokine response to IAV. We differentiated a 440 
hIPSC line with a biallelic mutation in IRF5 generated using CRISPR/Cas9 genome editing 441 
(16) and the parental line Kolf2, into iPS-DCs using a published differentiation strategy (24). 442 
We also generated a complemented isogenic control line for IRF5
-/-
 (hereafter “IRF5Comp”) to 443 
confirm IRF5-dependency of any phenotypes observed (32). To confirm gene editing 444 
strategies, we examined the expression of IRF5 in Kolf2, IRF5
-/-
 and IRF5
Comp
 iPS-DCs. 445 
IRF5 mRNA was detected in Kolf2 iPS-DCs but not IRF5
-/-
 iPS-DCs, with expression 446 
restored in IRF5
Comp
 iPS-DCs (Fig. 4A). Similar restoration of IRF5 protein expression in 447 
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IRF5
Comp
 iPS-DCs was observed (Fig. 4B). Furthermore, after infection of iPS-DCs with 448 
IAV, IRF5 was detected in Kolf2 iPS-DCs and not IRF5
-/-
 iPS-DCs by immunostaining (Fig. 449 
4C).  We then compared IAV-induced cytokine production by iPS-DCs from our healthy 450 
control iPSC line Kolf2 with monocyte-derived DCs from the blood of three healthy donors 451 
which were left either immature or matured for 48 hours with LPS. iPS-DCs demonstrated 452 
similar cytokine profiles after IAV infection to immature monocyte-derived DCs (Fig. 4D), 453 
validating iPS-DCs as an experimental system for examining virus-induced cytokine 454 
responses. 455 
 456 
It has previously been shown that IRF5 deficiency or TALEN-based engineering targeting 457 
the AAVS1 viral integration site does not affect the differentiation capacity of iPSCs to iPS-458 
derived macrophages (iPSDMs) (16, 33). To ensure that genome editing strategies had not 459 
altered the differentiation capacity of iPSCs to dendritic cells, we assessed the differentiation 460 
efficiency of Kolf2, IRF5
-/-
 and IRF5
Comp
 iPSCs. We observed similar numbers of cells 461 
harvested from embryoid bodies (EBs) from day 19-24 of differentiation, with no significant 462 
difference in the number of cells harvested from eight independent differentiations per line 463 
(Fig. 5A). After completion of the 25-day DC differentiation, DC marker expression was 464 
examined by flow cytometry, with CD141, CLEC9A, CD11c, MHC II and CD86 similarly 465 
expressed in all three iPS-DC lines (Fig. 5B). There are three main subsets of human DCs, 466 
pDCs and two subsets of myeloid (conventional) DCs, CD1c
+
 and CD141
+
, with DC 467 
hematopoiesis distinct from the development of monocytes (34).  iPS-DCs express markers 468 
of human conventional DCs including CD11c and CD141 (Fig. 5B), as well as HLA-DR, 469 
CD86 and CLEC9A, which have been shown to be expressed by human CD141
+
 DCs (35). 470 
We did not detect CD303 expression, a marker for pDCs or CD1c, the marker for the other 471 
subset of human conventional dendritic cells (36). As observed by Sachamitr et al (24) we 472 
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also detected CD14 and DC-SIGN expression by iPS-DCs (Forbester J & Humphreys I, 473 
unpublished data). Gene expression analysis confirmed similar induction of the DC markers 474 
CD83 and CD86 in all three iPSC lines after differentiation to iPS-DCs, and loss of 475 
expression of the pluripotency markers NANOG and POU5F1 (Fig. 5C). Morphology of 476 
Kolf2, IRF5
-/-
 and IRF5
Comp
 iPS-DCs in culture was indistinguishable (Fig. 5D). Taken 477 
together, these data suggest that neither IRF5 deficiency nor TALEN-based engineering 478 
influence iPSC differentiation. 479 
 480 
IRF5 enhances IAV-induced inflammatory cytokine production in iPS-DCs      481 
After confirming that IRF5 deficiency did not alter iPS-DC surface phenotype or morphology 482 
(Fig. 5) and that iPS-DCs exhibit similar cytokine profiles to human monocyte-derived DCs 483 
after IAV stimulation (Fig. 4D), we next used iPS-DCs to determine whether IRF5 has a cell-484 
intrinsic role in human DC cytokine production, in particular the pro-inflammatory cytokines 485 
IL-6 and TNF-. Despite a protective role for IL-6 being reported in murine models of IAV 486 
infection (37, 38), high production of IL-6 is linked to severity of symptoms in humans 487 
patient cohorts (39, 40), whereas TNF- has been shown to enhance cellular inflammation 488 
and pathology during IAV infection (26). 489 
 490 
24 hours after stimulation of iPS-DCs with IAV, IL-6 and TNF- production by IRF5-/- iPS-491 
DCs was significantly reduced in comparison to Kolf2 iPS-DCs whereas cytokine production 492 
was restored in IRF5
Comp
 iPS-DCs (Fig. 6A, iPS-DCs). IRF5 deficiency had no impact on 493 
virus entry, as indicated by comparable influenza nucleoprotein (NP) staining after 24 hours 494 
(Fig. 6B & C). In addition, there was no significant difference in cell viability after IAV 495 
stimulation, as measured by live viability dye and flow cytometry 24h p.i. (Mean  SEM % 496 
live cells: IRF5
Comp
, 65.767  0.353; IRF5-/-, 63.95  1.655; Kolf2, 70  1.654). Surface 497 
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analysis of DC markers by flow cytometry showed that the number of iPS-DCs expressing 498 
DC maturation markers after IAV infection was similarly significantly increased in Kolf2, 499 
IRF5
-/-
 and IRF5
Comp
 iPS-DCs (Fig. 6D). Moreover, gene complementation has previously 500 
been used to inhibit immune responsiveness in the context of restoration of expression of the 501 
inhibitory IL-10 receptor into IL10RB
-/-
 iPS-derived myeloid cells (33). Thus we do not 502 
believe that restored cytokine responsivess of complemented IRF5
-/- 
cells is a consequence of 503 
non-specific induction of cytokine secretion by the complementation process, but instead is 504 
due to IRF5 itself. Collectively, these data suggest that IRF5 deficiency selectively alters iPS-505 
DC cytokine production after exposure to IAV. In addition, to probe IRF5 deficiency in a 506 
different myeloid cell lineage, we differentiated IRF5
-/-
, Kolf2 and IRF5
Comp
 iPSCs to 507 
macrophages (iPSDMs) using a slightly modified version of a previously published protocol 508 
(22), demonstrating a similar significant reduction in IL-6 and TNF- production as observed 509 
in iPS-DCs (Fig. 6A, iPSDMs).  510 
 511 
IRF5 acts downstream of TLR7 and, possibly, RIG-I signalling pathways to drive 512 
human myeloid cell cytokine responses to IAV 513 
In some experimental systems, IRF5 mediates virus-induced production of type I IFN (17, 514 
41).  Given that type I IFN is implicated in driving influenza-induced inflammatory cytokine 515 
responses (42), we assessed whether IRF5 deficiency impacted influenza-induced IFN 516 
production. Blocking type I IFN reduced IAV-induced IL-6 and TNF- production albeit, in 517 
the case of IL-6, not to levels produced by IRF5
-/-
 iPS-DCs (Fig. 7A). Furthermore, IRF5 had 518 
no impact on type I IFN secretion by iPS-DCs (Fig. 7B). Thus, although type I IFN enhanced 519 
IRF5-induced pro-inflammatory cytokine secretion, the production of type I IFN by iPS-DCs 520 
was not an IRF5-regulated process. 521 
 522 
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We next investigated which PRRs require IRF5 to elicit cytokine responses following IAV 523 
stimulation of iPS-DCs. IAV is detected by endosomal TLR7, and members of the DExDC 524 
helicase family and RIG-I in dendritic cells (43–45). Consistent with data from human and 525 
murine macrophages (12, 46), IRF5
-/-
 iPS-DCs produced significantly less IL-6 in response to 526 
agonists of TLR7 (and TLRs 4, 3 and 9, Fig. 8A). Moreover, stimulation of IRF5
-/-
 iPS-DCs 527 
with the RIG-I-specific agonist 3p-hpRNA led to a significant reduction in IL-6 production 528 
(Fig. 8B), demonstrating that IRF5 mediates RIG-I- and TLR7-induced responses in iPS-529 
DCs. Substantial IFN-dependent induction of the RIG-I encoding gene DDX58 and, to a 530 
lesser extent, TLR7 were observed upon IAV stimulation of iPS-DCs (Fig. 8C & D), and 531 
IRF5 deficiency did not impair baseline PRR expression (Fig. 8E), suggesting that reduced 532 
expression of pro-inflammatory cytokines in response to TLR7, RIG-I and IAV stimulation 533 
in IRF5
-/-
 iPS-DCs was not a consequence of restricted PRR expression by these cells. 534 
 535 
Finally, we wanted to determine which PRRs mediated IAV-induced cytokine responses in 536 
iPS-DCs. Because 1) there is no selective antagonist of RIG-I and 2) human CD141
+
 DCs 537 
express TLR7 (47), we focused on the role of TLR7 in mediating IAV-induced iPS-DC 538 
cytokine responses. Addition of the specific TLR7 antagonist ODN 20958 to IAV-stimulated 539 
Kolf2 iPS-DCs significantly abated IL-6 production whereas TLR7 inhibition in IRF5
-/-
 iPS-540 
DCs did not further reduce IAV-induced IL-6 responses (Fig. 8F). These data suggest that 541 
IRF5 promotes TLR7 mediated cytokine responses following IAV detection by human DCs. 542 
However, IAV-induced cytokine secretion was incompletely inhibited by TLR7 blockade in 543 
Kolf2 iPS-DCs, suggesting that other PRRs contribute to IRF5-mediated responses. IKK 544 
has been shown to play a crucial role in IRF5 and NF-B activation (11). In support of this, 545 
pre-treatment of IAV-stimulated iPC-DCs with the IKK inhibitor IMD 0354 dramatically 546 
reduced IAV-induced cytokine production by iPS-DCs (Fig. 8B) implying that other PRRs 547 
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including, possibly, RIG-I contribute to IAV-induced cytokine responses by iPS-DCs in 548 
addition to TLR7. 549 
 550 
Discussion 551 
Here, using iPS-DCs as a model system, we have shown that IRF5 expression by myeloid 552 
cells is important in driving the inflammatory response to IAV, without impacting viral 553 
uptake by iPS-DCs or DC maturation. Using various blocking assays and stimulation with 554 
TLR/RLR ligands, we show that IRF5 is most likely acting downstream of TLR7 and, 555 
possibly, RIG-I signaling to drive the production of pro-inflammatory cytokines.  556 
 557 
Given that IFN-stimulated genes contribute to anti-influenza immunity (48), to identify 558 
whether IFR5 and/or related pathways could be safely exploited to dampen inflammatory 559 
cytokine responses to influenza it is important to understand the relationship between IRF5 560 
and virus-induced type 1 IFN. We found that IRF5
-/-
 iPS-DCs and Irf5
-/-
 mice were not 561 
deficient in type I IFN production, but that type I IFN enhances the IRF5-mediated 562 
inflammatory cytokine response, a process associated with IFN-mediated induction of TLR7 563 
and RIG-I. Although certain studies have reported a role for IRF5 in type I IFN induction 564 
directly in certain contexts (28, 46, 49) functional redundancy between IRF proteins may 565 
exist [46]. Also, although a role for IRF5 in promoting type 1 IFN secretion following 566 
influenza infection in vivo has been reported, the same studies observed reduced virus 567 
replication in Irf5
-/-
 mice, precluding the possibility to uncouple decreased virus replication 568 
and subsequent pattern recognition receptor stimulation from a direct influence of IRF5 on 569 
type 1 IFN expression. Furthermore, early in vivo studies of Irf5 responses to viruses may 570 
have been confounded by a Dock2 mutation prevalent in Irf5
-/-
 mouse colonies (50). Also, it 571 
has been demonstrated in vitro that, unlike IRF3 and IRF7, IRF5 does not bind to the virus-572 
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response elements in IFN promotors (51). IRF5-mediated induction of type I IFN may also be 573 
virus-specific, at least in vitro, with NDV, VSV and HSV-1 infection shown to activate IRF5 574 
but lead to induction of distinct IFNA gene subtypes in human cell lines (52). IRF3 and IRF7 575 
are activated by IAV, and these transcription factors have been shown to be necessary for 576 
inducing type I IFN after IAV infection (53, 54). Therefore, we suggest that after sensing of 577 
IAV by dendritic cells, IRF3, IRF5, and IRF7 are induced, resulting in the production of type 578 
I IFN and inflammatory cytokines, with the type I IFN induced by IRF3 and IRF7 579 
exacerbating IRF5 activation, likely in part through induction of TLR7 and, possibly, RIG-I 580 
expression. In the context of influenza pathogenesis, our data imply that IRF5 could be safely 581 
targeted to limit virus-induced pro-inflammatory cytokine production without affecting IFN 582 
production and associated induction of antiviral effector genes. 583 
 584 
The phenotype of reduced inflammatory cytokines observed in our iPS-DC model was also 585 
evident in vivo using Irf5
-/-
 mice. Although we observed no mortality in either WT or Irf5
-/-
 586 
mice (Forbester J & Humphreys I, unpublished data), we observed reduced cytokine 587 
production by myeloid cells that correlated with reduced cellular pulmonary infiltration and a 588 
moderate impact on virus-induced weight loss. Although Irf5
-/-
 mice have previously been 589 
shown to be less susceptible to IAV-induced pathology (28), in this study we were able to de-590 
couple viral load and inflammatory cytokines in the early stages of infection, demonstrating 591 
that the enhanced pathology in WT compared to Irf5
-/-
 mice was immune-mediated rather 592 
than a consequence of heightened virus replication. Why differences exist between our data 593 
and those obtained by Chen et al (28) is unclear, although this may reflect the different 594 
influenza strains (H3N2 versus H1N1) used in these experiments. Irrespective, the data 595 
presented herein demonstrates that IRF5 modulates viral pathogenesis via the regulation of 596 
inflammation and not virus replication, and that targeting this pathway as an adjunct therapy 597 
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to antiviral drug treatment may represent an effective therapeutic approach to treatment of 598 
influenza pathogenesis. 599 
 600 
Although the mouse provides a useful model to study viral pathogenesis there are inherent 601 
immunological differences between mice and humans (55). Therefore, we wanted to establish 602 
a human cell system amenable to genetic manipulation, so that gene function can be 603 
understood in the context of a human cellular environment. Given that primary human 604 
myeloid cells are difficult to genetically manipulate and access in large numbers, hIPSCs 605 
offer a solution; once hIPSCs are generated they can be differentiated down multiple cellular 606 
lineages, providing the opportunity to study gene function in multiple different cell types, 607 
with a defined genetic background. In addition, as hIPSCs are self-renewing, starting material 608 
is an unlimited resource. Furthermore, many research groups have shown that hIPSCs can be 609 
relatively easily genetically manipulated using tools such as Zinc finger nucleases, TALENs 610 
and CRISPR-Cas9 systems (56). Here, we show that iPSCs can be differentiated into DCs 611 
expressing markers of human CD141
+
 myeloid DCs. However, the levels of the specific 612 
lineage markers for CD141
+
 DCs, CLEC9A and XCR1 were quite low in our DC 613 
populations, which has been previously described (24). The complex environment and array 614 
of signals DC progenitors are exposed to during development presents a challenge to 615 
replicate in vitro. However, fundamental understanding of human DC development is 616 
expanding, and in the future knowledge of detailed changes in the transcriptional profile of 617 
these cells during development can be applied to help refine differentiation protocols. 618 
However, iPS-DCs described herein expressed multiple DC lineage markers, suggesting that 619 
our differentiation protocol is sufficient to derive DC-like cells. In addition, we demonstrated 620 
that after differentiation into iPSDMs, IRF5
-/-
 cells are also deficient in IL-6 and TNF- 621 
production, demonstrating for the first time that virus induced immune responses, including 622 
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cytokine secretion, can be investigated in iPS-derived cells of multiple myeloid lineages that 623 
contain biallelic mutations, thus demonstrating the flexibility of iPSCs as tools to study 624 
immune responses to pathogens in multiple cell types.  625 
  626 
In two independent studies response eQTLs (reQTLs) were found in IRF5 after stimulation of 627 
cells with virus or TLR ligands (57, 58), suggesting that variation within the IRF5 locus may 628 
be important in driving differences in expression. It would be interesting in future studies to 629 
see if SNPs which drive higher IRF5 expression in human macrophages and DCs also 630 
correlate with a heightened inflammatory response to viruses such as IAV, as our data 631 
suggest that such individuals may be preferentially susceptible to influenza pathogenesis and 632 
imply that targeting high IRF5 levels in these individuals could reduce inflammation without 633 
impacting virus control. As well as being a useful tool to knockout genes to assess cell-634 
specific function as we have shown here, iPS-DCs could also be used as a tool to explore 635 
how common human genetic variants are associated with immune cell responses to various 636 
pathogens.  637 
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Figure legends 860 
 861 
Figure 1. IRF5 alters cytokine responses to Influenza A virus in a murine infection 862 
model. WT and Irf5
-/-
 mice were infected intranasally with 3 x 10
3
 A/X-31 influenza (A) 863 
Inflammatory cytokine expression in BAL, was measured using multiplex assays 2, 4 and 7 864 
days p.i. Data shown as mean  SEM using 7 WT and 5 Irf5-/- mice (day 2) or five mice per 865 
genotype (day 4 and day 7) and represents two independent experiments. (B) IFN- and IFN-866 
 levels in BAL measured by ELISA in Irf5-/- and WT naïve and IAV infected mice 2 days 867 
p.i. Data shown as mean  SEM of 3-6 mice per group at 2 days p.i.  868 
 869 
Figure 2. IRF5 enhances Influenza A virus-induced inflammatory response in a murine 870 
infection model. (A) Weight loss of WT and Irf5
-/- 
mice was assessed over time and 871 
comparable results were observed in 4 independent experiments, with 4-5 WT or Irf5
-/-
 mice 872 
in each group per experiment. Data shown as mean  SEM. (B) Replicating virus in lung was 873 
quantified by plaque assay. Data shown as mean  SEM using 7 WT and 5 Irf5-/- mice for day 874 
2, and 5 mice of each genotype for day 4. (C) Recruitment of specific myeloid cell 875 
populations (mDCs, monocyte-derived DCs; cDCs, conventional DCs; pDCs, plasmacytoid 876 
DCs; Inflam. mon, inflammatory monocytes) in WT and Irf5
-/-
 mice was assessed by flow 877 
cytometry 2 days p.i. Populations were defined by the following markers: Alveolar 878 
macrophages - SiglecF
+ 
CD11b
+ 
CD64
+ 
Ly6C
-
; mDCs - SiglecF
-
 CD11b
+
 MHC II
+
 CD11c
+
 879 
CD64
+
 Ly6C
+
; Interstitial macrophages - SiglecF
-
 CD11b
+
 MHC II
+
 CD11c
-
 CD64
+
 Ly6C
+
; 880 
Inflammatory monocytes - Siglec F
-
 CD11b
+
 MHC II
-
 Ly6C
+
 CD64
+
; cDCs; MHC II
+
 881 
CD11c
+
 Ly6C
-
; pDCs – B220+ SiglecH+ MHC IIlow CD11clow; Eosinophils – SiglecF+ 882 
CD11c
-
 CD11b
+
 Ly6C
-
. Data shown as mean  SEM using 11 WT and 10 Irf5-/- mice from 883 
multiple replicates. (D) The total number of each individual myeloid cell population 884 
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(unstimulated, ex vivo) positive for IL-6 and TNF-⍺ expression by was detected by flow 885 
cytometry, with data presented representing mean total cell number per 10
5
 cells of each cell 886 
type  SEM. Data represents two experiments. 887 
 888 
Figure 3. IRF5 expression in human lung cells. IRF5 expression by multiple cellular 889 
subsets derived from human lung tissue from independent donors was analyzed by CyTOF. 890 
(A) UMAP based on down sampled, concatenated files from lung samples from four donors 891 
using phenotypic markers. Post UMAP analysis, populations (colored by cell type as 892 
identified by lung CyTOF) were defined via the following markers: CD4
+
 T cells, CD3
+ 
893 
CD4
+ 
CD20
-
; CD8
+
 T cells, CD3
+ 
CD20
- 
CD8
+
; B cells, CD3
- 
CD20
+
; NK cells, CD3
- 
CD20
- 
894 
CD56
+
; CD14
+
 Monocytes, CD16
- 
CD11b
+ 
CD14
+ 
HLA-DR
+
; CD16
+
 Monocytes, CD14
- 
895 
CD11b
+ 
CD16
+ 
HLA-DR
+
; Macrophages, CD11b
+ 
CD68
+ 
HLA-DR
+
; pDCs, CD123
+ 
CD11b
+ 
896 
HLA-DR
+
; CD141
+
 cDCs, CD11b
+ 
HLA-DR
+ 
CD1c
- 
CD141
+
; CD1c
+
 cDCs, CD11b
+ 
HLA-897 
DR
+ 
CD1c
+ 
CD141
-
; Eosinophils, Siglec8
+ 
CD123-; Basophils, Siglec8
+ 
CD123
+
 (B) Median 898 
IRF5 expression in populations identified in (A) from lung samples taken from four 899 
independent donors, corrected for non-specific staining using unpermeabilized controls for 900 
each sample, error bars represent  SEM. (C) Median IRF5 expression in myeloid vs 901 
lymphoid cell subsets, error bars represent  SEM. 902 
 903 
Figure 4. IRF5
-/- 
iPSCs, IRF5
Comp
 iPSCs and Kolf2 iPSCs can be differentiated into iPS-904 
DCs which lack or express IRF5. CRISPR/Cas9 was used to generate biallelic mutations in 905 
IRF5 in the Kolf2 background. IRF5
Comp
 iPSCs were generated using TALEN-mediated 906 
integration of IRF5 into the IRF5
-/-
 background. (A) Relative expression of IRF5 in iPSCs 907 
and iPS-DCs, relative to GAPDH. Data shown as four technical replicates per assay, with 908 
assays repeated three times from independent iPS-DC batches. (B) Flow cytometry showing 909 
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IRF5 expression in iPS-DCs generated from IRF5
-/-
, IRF5
Comp
 and Kolf2 iPSCs. (C) 910 
Immunostaining for IRF5 in A/X-31 influenza (IAV) infected Kolf2 and IRF5
-/- 
iPS-DCs 911 
(DAPI, blue; IRF5, green). (D) IL-6 and TNF-⍺ production 24h p.i. by A/X-31 influenza 912 
(IAV) challenged Kolf2 iPS-DCs and monocyte-derived DCs generated from human 913 
peripheral blood, either with or without 48h LPS maturation, was assayed by ELISA. Data 914 
represented shows mean  SEM from three independent Kolf2 differentiations for iPS-DCs, 915 
and from three independent healthy donors for monocyte-derived DCs.    916 
 917 
Figure 5. IRF5
-/- 
iPSCs, IRF5
Comp
 iPSCs and Kolf2 iPSCs can be differentiated into iPS-918 
DCs that display similar morphology. IRF5
-/- 
iPSCs, IRF5
Comp
 and Kolf2 iPSCs were 919 
differentiated into dendritic cells using defined concentrations of growth factors to generate 920 
embryoid bodies (EBs), and GM-CSF and IL-4 to generate immature DCs from these EBs. 921 
(A) Total cell numbers of DC precursors harvested from DC differentiation plates. Data 922 
shown as 8 independent differentiations per iPSC line. (B) Surface expression of DC markers 923 
was examined via flow cytometry in Kolf2, IRF5
-/-
 and IRF5
Comp
 iPS-DCs. Representative 924 
plots presented from one experiment, with experiments performed at least three times. (C) 925 
Gene expression of DC markers CD83 and CD86 and iPSC markers NANOG and POU5F1 926 
by iPS-DCs, relative to GAPDH was quantified using TaqMan gene-expression assays. Data 927 
shown represents four technical replicates per assay, with assays repeated at least twice from 928 
independent iPS-DC batches. (D) Morphology of iPS-DCs generated from Kolf2, IRF5
Comp
 929 
and IRF5
-/-
 iPSCs. 930 
 931 
Figure 6. IRF5 enhances IAV-induced inflammatory cytokine production in iPS-DCs 932 
and iPSDMs. (A) IL-6 and TNF- were measured by ELISA in supernatants harvested from 933 
iPS-DCs and iPSDMs generated from an iPSC line with a biallelic mutation in IRF5, 934 
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compared to the parent line Kolf2, and a line with a functional IRF5 gene reintroduced into 935 
the AAVS1 integration site by TALEN engineering, after infection with IAV at MOI 1. 936 
Supernatants were harvested at 24 hours for assays; data shown represents mean  SEM for 937 
triplicate wells from at least 3 independent experiments. (B) IRF5
-/-
, IRF5
Comp
 and Kolf2 iPS-938 
DCs were infected with IAV at MOI 1, and then stained for IAV NP 24 hours post-infection 939 
and analyzed via flow cytometry (C) % positive NP iPS-DCs 24-hour IAV post-infection, 940 
with data presented showing mean  SEM from three independent experiments. (D) 941 
Expression of DC maturation surface markers for iPS-DCs generated from IRF5
-/-
, Kolf2 or 942 
IRF5
Comp
 hIPSCs 24-hour post-infection with A/X-31 influenza (IAV), MOI 1, as measured 943 
by flow cytometry, with data presented showing mean  SEM from three independent 944 
experiments.  945 
   946 
Figure 7. Type I IFN signaling enhances IL-6 and TNF-⍺ production by iPS-DCs. 2 x 947 
10
4
 iPS-DCs were challenged as stated below for each assay, and supernatants were 948 
harvested after 24 hours, unless otherwise stated. A/X-31 influenza (IAV) was used at MOI 949 
1. (A) Cells were pre-incubated for 1-hour with anti-IFNAR1 antibody, or left untreated prior 950 
to viral infection. Data shown represents mean  SEM for triplicate wells from at least 3 951 
experiments. Supernatants were harvested and assayed for IL-6 and TNF-⍺ by ELISA. (B) 952 
Supernatants from mock or IAV-infected Kolf2 or IRF5
-/- 
iPS-DCs were harvested at 24 953 
hours and assayed for IFN-⍺ and IFN- by ELISA. Data shown represents 2 separate 954 
experiments. 955 
 956 
Figure 8. IRF5 acts downstream of TLR7 and RIG-I to drive inflammatory cytokine 957 
responses in iPS-DCs. 2 x 10
4
 iPS-DCs were challenged as stated below for each condition 958 
in each assay and supernatants were harvested after 24 hours. A/X-31 influenza (IAV) was 959 
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used at MOI 1. For blocking assays cells were either pre-incubated for 1 hour with inhibitor 960 
(IMD 0354; IKK inhibitor) or inhibitor was added directly with viral inoculum (ODN 961 
20958; TLR7 inhibitor). Data shown represents mean  SEM for triplicate wells from at least 962 
3 experiments, unless otherwise stated. (A) IL-6 production by Kolf2 and IRF5
-/- 
iPS-DCs in 963 
response to stimulation with various TLR ligands (TLR2: Pam3CSK4, 300 ng/mL; TLR3: 964 
Poly I:C, 50 g/mL; TLR4: LPS, 50 g/mL; TLR7: Imiquimod, 50 g/mL; TLR9: ODN 965 
2216, 3 g/mL) was measured by ELISA. Data shown represents four wells per condition for 966 
one iPS-DC batch per line, with assays replicated in two independent experiments. (B) IL-6 967 
response as measured by ELISA in Kolf2 and IRF5
-/-
 iPS-DCs to RIG-I ligand 3p-hpRNA 968 
with or without IKKβ inhibitor IMD 0354; and to A/X-31 influenza (IAV) with or without 969 
IMD 0354. (C) Fold-change in mRNA levels for TLR7 and DDX58, measured by RT-qPCR 970 
using GAPDH as an endogenous control. (D) DDX58 and TLR7 mRNA levels in iPS-DCs 971 
after A/X-31 influenza (IAV) infection with or without blocking of type I IFN signaling 972 
using anti-IFNAR1. Data shown represents four technical replicates per assay, with assays 973 
repeated at least twice from independent iPS-DC batches. (E) Relative mRNA levels of TLR7 974 
in iPS-DCs generated from IRF5
-/-
 iPSCs or parent Kolf2 iPSCs, measured using RT-qPCR. 975 
(F) IL-6 response as measured by ELISA in Kolf2 and IRF5
-/-
 iPS-DCs to A/X-31 influenza 976 
with or without TLR7 inhibitor ODN 20958. 977 
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Figure 1.  
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Figure 2.  
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Figure 3.  
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Figure 4.  
 
iPS
Cs
iPS
-
DC
s
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
G
en
e 
ex
pr
es
sio
n
 
re
la
tiv
e 
to
 
G
AP
D
H
Kolf2
IRF5-/-
IRF5Comp
****
n.s.
Kolf2
IRF5-/-
IRF5Comp
Unstained
Mo
ck
IAV
 
MO
I 1
0
500
1000
1500
IL
-
6 
(pg
/m
l)
n.s.
n.s.
Mo
ck
IAV
 
MO
I 1
0
500
1000
1500
TN
Fa
 
(pg
/m
l)
*
n.s.
B
C
DA
DAPI
IRF5
IRF5-/-
IAV
Kolf2
IAV
iPS-DCs Mon DCs
+ LPS
Mon DCs
 o
n
 M
arch 2, 2020 at CAM
BRIDG
E UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
 5 
 
Figure 5.  
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Figure 6.  
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Figure 7.  
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Figure 8.  
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